Verona Pharma price target raised to $72 from $44 at Canaccord
Canaccord raised the firm’s price target on Verona Pharma (VRNA) to $72 from $44 and keeps a Buy rating on the shares. The firm believes the ...
pharmaphorum3d
Verona’s first-in-class COPD drug ‘could transform market’
Verona Pharma has claimed FDA approval for its ... killing more than three million people in 2019, according to World Health Organization (WHO) estimates. The massive number of patients with ...
pharmaphorum5d
Verona cuts $400m loan deal as it preps COPD drug for market
Verona Pharma has agreed a new $400 million debt facility with Oxford Finance and Hercules Capital designed to help the company navigate the possible approval and launch of ensifentrine, its ...
CNN6y
Verona Pharma plc Sponsored ADR
Verona Pharma Plc engages in the development and commercialization of therapeutics for the treatment of respiratory diseases. It focuses on developing inhaled ensifentrine for the maintenance ...
Hosted on MSN25d
Is Verona Pharma (VRNA) Among Billionaire Joseph Edelman’s Long-Term Stock Picks?
In this article, we are going to take a look at where Verona Pharma plc (NASDAQ ... Joseph Edelman is a renowned figure in the investment world, recognized for his expertise in biotechnology ...